The influence of methylprednisolone on the ability of CD4+CD95+HLA-DR+ T-cells to produce proinflammatory medators in cultures of TCR-activated CD3+CD45RO+ T-lymphocytes from patients with rheumatoid arthritis
The effect of different concentrations of the glucocorticoid (GC) methylprednisolone (MP) on CD4+CD95+HLA-DR+ T-cells and their ability to produce proinflammatory mediators in cultures of TCR-stimulated CD3+CD45RO+ T-lymphocytes in the in vitro system was investigated. T cells were obtained from healthy donors and patients with rheumatoid arthritis (RA).Under conditions of TCR-activation, MP increased the number of CD4+HLA-DR+CD95+ cells in CD3+CD45RO+ cultures obtained from RA patients and did not change their content in the control group. In general, MP decreased production of proinflammatory factors (IFN-, IL-2, IL-17, IL-21 and TNF-) by TCR-activated CD3+CD45RO+ cells from healthy donors and RA, consistent with the overall immunosuppressive mechanism of GC action. The correlation between CD4+CD45RO+HLA-DR+CD95+ T-cell contents and parameters reflecting production of proinflammatory mediators (IL-17, IL-21 and TNF-) in RA patients indicates maintenance of the pro-inflammatory potential of this T-cell population exposed to GC action. We suggest that relative resistance of CD4+CD45RO+CD95+HLA-DR+ T-cells of RA patients to the suppressor effect of GC leads to maintenance and even enhancement in the functional capacities of autoreactive cells in the pathogenesis of RA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Biomeditsinskaia khimiia - 63(2017), 3 vom: 04. Mai, Seite 255-265 |
| Sprache: |
Russisch |
|---|
| Weiterer Titel: |
Vliianie metilprednizolona na sposobnost' CD4+CD95+HLA-DR+ T-kletok v kul'turakh TCR-aktivirovannykh CD3+CD45RO+ T-limfotsitov bol'nykh revmatoidnym artritom produtsirovat' provospalitel'nye mediatory |
|---|
| Beteiligte Personen: |
Todosenko, N M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.09.2017 Date Revised 22.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18097/PBMC20176303255 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM274550695 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM274550695 | ||
| 003 | DE-627 | ||
| 005 | 20231225003729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.18097/PBMC20176303255 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0915.xml |
| 035 | |a (DE-627)NLM274550695 | ||
| 035 | |a (NLM)28781259 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Todosenko, N M |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The influence of methylprednisolone on the ability of CD4+CD95+HLA-DR+ T-cells to produce proinflammatory medators in cultures of TCR-activated CD3+CD45RO+ T-lymphocytes from patients with rheumatoid arthritis |
| 246 | 3 | 3 | |a Vliianie metilprednizolona na sposobnost' CD4+CD95+HLA-DR+ T-kletok v kul'turakh TCR-aktivirovannykh CD3+CD45RO+ T-limfotsitov bol'nykh revmatoidnym artritom produtsirovat' provospalitel'nye mediatory |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.09.2017 | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The effect of different concentrations of the glucocorticoid (GC) methylprednisolone (MP) on CD4+CD95+HLA-DR+ T-cells and their ability to produce proinflammatory mediators in cultures of TCR-stimulated CD3+CD45RO+ T-lymphocytes in the in vitro system was investigated. T cells were obtained from healthy donors and patients with rheumatoid arthritis (RA).Under conditions of TCR-activation, MP increased the number of CD4+HLA-DR+CD95+ cells in CD3+CD45RO+ cultures obtained from RA patients and did not change their content in the control group. In general, MP decreased production of proinflammatory factors (IFN-, IL-2, IL-17, IL-21 and TNF-) by TCR-activated CD3+CD45RO+ cells from healthy donors and RA, consistent with the overall immunosuppressive mechanism of GC action. The correlation between CD4+CD45RO+HLA-DR+CD95+ T-cell contents and parameters reflecting production of proinflammatory mediators (IL-17, IL-21 and TNF-) in RA patients indicates maintenance of the pro-inflammatory potential of this T-cell population exposed to GC action. We suggest that relative resistance of CD4+CD45RO+CD95+HLA-DR+ T-cells of RA patients to the suppressor effect of GC leads to maintenance and even enhancement in the functional capacities of autoreactive cells in the pathogenesis of RA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD95 | |
| 650 | 4 | |a HLA-DR | |
| 650 | 4 | |a glucocorticoid hormones | |
| 650 | 4 | |a memory T cell | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a CD2 Antigens |2 NLM | |
| 650 | 7 | |a CD3 Complex |2 NLM | |
| 650 | 7 | |a CD4 Antigens |2 NLM | |
| 650 | 7 | |a FAS protein, human |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a HLA-DR Antigens |2 NLM | |
| 650 | 7 | |a Interleukin-17 |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a Interleukins |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a fas Receptor |2 NLM | |
| 650 | 7 | |a Leukocyte Common Antigens |2 NLM | |
| 650 | 7 | |a EC 3.1.3.48 |2 NLM | |
| 650 | 7 | |a interleukin-21 |2 NLM | |
| 650 | 7 | |a MKM3CA6LT1 |2 NLM | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 700 | 1 | |a Khaziakhmatova, O G |e verfasserin |4 aut | |
| 700 | 1 | |a Yurova, K A |e verfasserin |4 aut | |
| 700 | 1 | |a Malinina, I P |e verfasserin |4 aut | |
| 700 | 1 | |a Litvinova, L S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomeditsinskaia khimiia |d 2003 |g 63(2017), 3 vom: 04. Mai, Seite 255-265 |w (DE-627)NLM142863602 |x 2310-6972 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2017 |g number:3 |g day:04 |g month:05 |g pages:255-265 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18097/PBMC20176303255 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2017 |e 3 |b 04 |c 05 |h 255-265 | ||